Defining and treating moderate plaque psoriasis: a dermatologist survey
نویسندگان
چکیده
منابع مشابه
Treating pediatric plaque psoriasis: challenges and solutions
Psoriasis is a T-lymphocyte-mediated chronic inflammatory disorder involving the skin and joints. Nearly 3.5% of the population has been diagnosed to have psoriasis. In a dermatology department, almost one-third of psoriasis patients are in the pediatric age group. With an annual prevalence of up to 0.71%, childhood psoriasis can now be regarded as a frequently seen chronic inflammatory skin di...
متن کاملManagement of Moderate to Severe Plaque Psoriasis
cancer, arthritis, hypertension, heart disease, diabetes, and depression (Rapp 1999). In the last decade, a new understanding about the pathophysiology of psoriasis has resulted in the development of a new class of agents for these patients: targeted biologic therapy. These novel treatments target specific immunologic processes involved in the genesis of this disease, providing significant clin...
متن کاملA Randomized Comparative Study Between Three Times And Five Times Weekly Phototherapy With NBUVB For Treating Chronic Plaque Type Psoriasis
Background: Psoriasis is a chronic inflammatory skin disease that is estimated to affect 0.6% to 4.8% of the general population. The optimum number of NB-UVB phototherapy sessions is yet to be determined. The aim of this study was to compare therapeutic effects of NB-UVB in treating chronic plaque type psoriasis three times weekly vs. five times weekly. Materials and Methods: This study was des...
متن کاملDermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis
INTRODUCTION The objective of the study was to determine the relative importance (RI) of treatment attributes psoriasis patients and physicians consider when choosing between biologic therapies based on psoriasis severity. METHODS A discrete choice experiment (DCE) weighting preference for eight sets of hypothetical treatments for moderate or severe psoriasis was conducted. DCE hypothetical t...
متن کاملIxekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
The National Institute for Health and Care Excellence invited Eli Lilly and Company Ltd, the company manufacturing ixekizumab (tradename Taltz®), to submit evidence for the clinical and cost effectiveness of ixekizumab. Ixekizumab was compared with tumour necrosis factor-α inhibitors (etanercept, infliximab, adalimumab), ustekinumab, secukinumab, best supportive care and, if non-biological trea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Dermatological Treatment
سال: 2018
ISSN: 0954-6634,1471-1753
DOI: 10.1080/09546634.2018.1443200